Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
暂无分享,去创建一个
E. Jaffe | R. Fisher | P. Duffey | D. Longo | V. Devita | J. Cossman | D. Ihde | S. Hubbard | M. Gilliom | M. Wesley
[1] E. Jaffe,et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Weisenburger,et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Shank,et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Papish,et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Hryniuk Wm. The importance of dose intensity in the outcome of chemotherapy. , 1988 .
[6] K. Anderson,et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. , 1987, The New England journal of medicine.
[7] J. Armitage,et al. High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. , 1986, European journal of cancer & clinical oncology.
[8] R. Fisher,et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. , 1986, Annals of internal medicine.
[9] A. Goldstone,et al. Clinical studies of ABMT in non-Hodgkin's lymphoma. , 1986, Clinics in haematology.
[10] D. Weisenburger,et al. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Biron,et al. Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphoma , 1985, British journal of haematology.
[12] F. Mandelli,et al. Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). , 1985, Seminars in oncology.
[13] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[14] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[15] J. Armitage,et al. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Fay,et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. , 1984, The New England journal of medicine.
[17] R. Fisher,et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.
[18] G. Pinkus,et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Pasmantier,et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.
[20] J. Ultmann,et al. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. , 1980, Annals of internal medicine.
[21] K. Rothman. Estimation of confidence limits for the cumulative probability of survival in life table analysis. , 1978, Journal of chronic diseases.
[22] D. Rosenthal,et al. Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). , 1977, Blood.
[23] C. Coltman,et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.
[24] V. Devita,et al. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. , 1976, Annals of internal medicine.
[25] V. Devita,et al. ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY , 1975, The Lancet.
[26] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[27] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[28] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .